[iito] Business Intelligence – The Elephants Are Coming 560x91px
Organisation › Details

Themis Bioscience GmbH

Themis Bioscience GmbH develops prophylactic vaccines from the preclinical to the early clinical phase, focusing on infectious diseases, with initial vaccine candidates currently being developed against Chikungunya and Zika. The company's highly innovative and fully patent-protected virus vaccine vector technology platform, licensed from the internationally respected Institut Pasteur in Paris, forms the basis for the current vaccine candidates of the Vienna-based company. *


Period Start 2009-09-01 established
  Group Themis Bioscience (Group)
Product Industry vaccine
Person Person Tauber, Erich (Themis Bioscience GmbH 201505 CEO)
Region Region Wien (Vienna)
  Country Austria
  Street 11/2 Muthgasse
  City 1190 Wien
  Tel +43-1-236-7151
    Address record changed: 2018-11-02
Basic data Employees A: 1 to 10 (2015-09-22)
    * Document for �About Section�: Themis Bioscience GmbH. (7/12/16). "Press Release: New Worldwide, Exclusive License Agreement Provides Broad Access to Institut Pasteur's Virus Vector Technology – Zika Vaccine Development Progressing with High Priority". Vienna.
Record changed: 2019-08-28


Picture [LSUS] – The Business Web Portal 650x112px

More documents for Themis Bioscience (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSUS] – The Business Web Portal 600x60px

» top